Three-min Step Test and Exercise Desaturation Detection in Chronic Respiratory Insufficiency Patients (STEPSAT)

June 30, 2025 updated by: University Hospital, Limoges

Ability of the 3-minute Step Test Protocol for Detecting Exercise Desaturation Episodes in Chronic Respiratory Insufficiency: Protocol STEPSAT: Three-min Step Test and Exercise Desaturation Detection in Chronic Respiratory Insufficiency Patients

The study project will aim at the evaluation of the occurrence of exercise desaturation phenomenon during two different modalities of exercise (walking and stepping condition). This study will allow determining the sensibility of the 3-minute step test to detect exercise desaturation, in comparison with the gold standard (6-minute walking test). The 3-minute step test could therefore appear as a complementary tool for the evaluation of oxygen desaturation in chronic respiratory disease.

Study Overview

Detailed Description

The 6-minute walking test is currently the gold standard for the evaluation of oxygen desaturation phenomenon during exercise and for the adjustment of O2 flow rate. But, due to spatial constraints, this test remains difficult to apply in ecological conditions and the 3-minute step test could be a complementary method to the walking test for the evaluation of chronic respiratory diseases. For this study, patients will perform, during 2 visits, a maximal graded test and two field tests (6-min walking test and 3-min step test) under identical conditions. During these tests, pulsed oxygen saturation and psycho-physiological adaptations to exercise will be monitored.

Study Type

Interventional

Enrollment (Actual)

27

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Limoges, France, 87000
        • CHU de Limoges

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients aged by 18 and more ;
  • Patient with an chronic obstructive respiratory insufficiency, confirmed by clinical and functional criteria ;
  • Patient with exercise-induced oxygen desaturation ;
  • Patient clinical ly stable, with no exacerbation period within the last 2 months before inclusion ;
  • Consent form signed by the patient.

Exclusion Criteria:

  • Patient in exacerbation period at the inclusion time ;
  • Pregnant and breastfeeding women ;
  • Patient with orthopedic disorder that could limit the ability of stair climbing;
  • Any other disease that could influence exercise capacity of the patient or that could impair exercise test realization ;
  • Patient with law protection (guardianship or protection of vulnerable adults)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Three-min Step Test and Exercise desaturation detection in COPD
Each patient recruited will performed both field tests, being therefore his or her own witness.
For this research, 2 visits will be scheduled (V1 and V2) for each patient. During V1, after collecting the filled and signed consent form from the patient, anthropometric measurements and pulmonary function assessment will be performed before the realization of a maximal graded test. This inclusion visit will be carried out as part of an inclusion within a respiratory rehabilitation program. During V2, each patient will randomly perform a 6-minute walking test and a 3-minute step test, in similar standard conditions. A 30-minute resting period will be allowed between the two field tests. During the realization of the tests, cardio-respiratory adaptations will be monitored throughout both tests with portable gas analyzer and pulsed oxymetry system.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Detection of exercise desaturation occurrence
Time Frame: At Visit 2: between Day 3 and Day 15 after Visit 1
Detection of exercise desaturation occurrence correspond to a fall of SpO2 rest value by at least 4 points during exercise, assessed with the measurement of pulsed oxygen saturation during the different tests.
At Visit 2: between Day 3 and Day 15 after Visit 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient-perceived sensation of dyspnea
Time Frame: At Visit 2: between Day 3 and Day 15 after Visit 1

scoring by Borg Category Ratio 10 scale (CR-10)

  • Scale going from 0 to 10
  • 0 being an absence of sensation, 10 a very high sensation or even maximum.
At Visit 2: between Day 3 and Day 15 after Visit 1
Patient-perceived sensation of lower extremity fatigue
Time Frame: At Visit 2: between Day 3 and Day 15 after Visit 1

scoring by Borg Category Ratio 10 scale (CR-10)

  • Scale going from 0 to 10
  • 0 being an absence of sensation, 10 a very high sensation or even maximum.
At Visit 2: between Day 3 and Day 15 after Visit 1
Oxygen consumption (VO2)
Time Frame: At Visit 2: between Day 3 and Day 15 after Visit 1

This parameter will be obtained from a measuring device (Metamax), allowing a real time measurement and its registration will be collected at the end of the walking and stepping tests.

Reported value in ml/min/kg : mean value of the last thirty seconds of each test.

At Visit 2: between Day 3 and Day 15 after Visit 1
CO2 production (VCO2)
Time Frame: At Visit 2: between Day 3 and Day 15 after Visit 1

This parameter will be obtained from a measuring device (Metamax), allowing a real time measurement and its registration will be collected at the end of the walking and stepping tests.

Reported value in ml/min/kg : mean value of the last thirty seconds of each test.

At Visit 2: between Day 3 and Day 15 after Visit 1
Ventilatory output (VE)
Time Frame: At Visit 2: between Day 3 and Day 15 after Visit 1

This parameter will be obtained from a measuring device (Metamax), allowing a real time measurement and its registration will be collected at the end of the walking and stepping tests.

Reported value in l/min : mean value of the last thirty seconds of each test.

At Visit 2: between Day 3 and Day 15 after Visit 1
Heart rate (HR)
Time Frame: At Visit 2: between Day 3 and Day 15 after Visit 1

This parameter will be obtained from a measuring device (Metamax), allowing a real time measurement and its registration will be collected at the end of the walking and stepping tests.

Reported value in Beats/min : mean value of the last thirty seconds of each test.

At Visit 2: between Day 3 and Day 15 after Visit 1
Muscle deoxygenation (delta HHb)
Time Frame: At Visit 2: between Day 3 and Day 15 after Visit 1

The assessment of muscle deoxygenation observed by near infrared spectroscopy (NIRS) technology.

Reported value in arbitrary unit : difference between mean HHb value at rest and the lowest HHb value during each exercise

At Visit 2: between Day 3 and Day 15 after Visit 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Florent FAVARD, MD, University Hospital, Limoges

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 15, 2022

Primary Completion (Actual)

October 24, 2023

Study Completion (Actual)

October 24, 2023

Study Registration Dates

First Submitted

May 20, 2021

First Submitted That Met QC Criteria

May 27, 2021

First Posted (Actual)

June 3, 2021

Study Record Updates

Last Update Posted (Actual)

July 3, 2025

Last Update Submitted That Met QC Criteria

June 30, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 87RI19-0003_STEPSAT

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Subscribe